Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
A phase 1/2 trial of Golidocitinib in peripheral T-cell lymphomas, run by Dizal Pharmaceuticals, now recruiting.
Overview
Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) is a phase 1/2 interventional study registered as NCT07496229 by Dizal Pharmaceuticals, with 165 participants planned, started 2026-04-15 and due to reach its primary completion in 2029-09. Interventions recorded: GW5282 combined with Golidocitinib and Conventional CHOP regimen.
Similar pages
not linked directly; found by shared links- TrialA Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Shares Golidocitinib, Dizal Pharmaceutical.
- TrialA Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors
Shares Dizal Pharmaceutical and the tag pipeline.
- TrialA Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialDZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
Shares Dizal Pharmaceutical and the tag pipeline.
- TrialDZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)
Shares Dizal Pharmaceutical and the tag pipeline.
- TrialA Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialA Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
Shares Dizal Pharmaceutical and the tag pipeline.
- TrialStudy to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.